These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 10066944)

  • 21. Adaptive biased-coin designs for skewing the allocation proportion in clinical trials with normal responses.
    Atkinson AC; Biswas A
    Stat Med; 2005 Aug; 24(16):2477-92. PubMed ID: 16007571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-arm clinical trials of new agents: some design considerations.
    Freidlin B; Korn EL; Gray R; Martin A
    Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developing drugs that do not cause tumor regression.
    Stadler W
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
    [No Abstract]   [Full Text] [Related]  

  • 25. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical equipoise and randomised clinical trials in oncology].
    Ferté C; Hollebecque A; Salleron J; Penel N
    Bull Cancer; 2009 Jun; 96(6):727-31. PubMed ID: 19470421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The method of conducting randomized trials in cancerology must be changed].
    Hill C
    Bull Cancer; 2002 Sep; 89(9):823-5. PubMed ID: 12368134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designing an acupuncture study to meet evidence-based medical criteria: methodological considerations for logistic design and development of treatment interventions arising from the German randomized controlled acupuncture trial on chronic shoulder pain (GRASP).
    Molsberger AF; Mau J; Gotthardt H; Schneider T; Drabik A
    Eur J Med Res; 2004 Aug; 9(8):405-11. PubMed ID: 15337631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current trials and new aspects in soft tissue sarcoma of adults.
    Issels RD; Schlemmer M
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The limits of controlled clinical studies: the case of rheumatology].
    Portioli I
    Ann Ital Med Int; 2000; 15(1):39-46. PubMed ID: 10842890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
    Mazumdar M; Fazzari M; Panageas KS
    Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous.
    Steensma DP
    J Clin Oncol; 2007 Mar; 25(9):1148; author reply 1148-9. PubMed ID: 17369584
    [No Abstract]   [Full Text] [Related]  

  • 36. The ethics of phase 0 oncology trials.
    Abdoler E; Taylor H; Wendler D
    Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design considerations for randomised trials in orthopaedic fracture surgery.
    Simunovic N; Devereaux PJ; Bhandari M
    Injury; 2008 Jun; 39(6):696-704. PubMed ID: 18502423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and analysis of prostate cancer trials.
    Sylvester R
    Acta Urol Belg; 1994 Apr; 62(1):23-9. PubMed ID: 8197926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cross-validated adaptive signature design.
    Freidlin B; Jiang W; Simon R
    Clin Cancer Res; 2010 Jan; 16(2):691-8. PubMed ID: 20068112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Status quo and problems in phase III trials: view of a trialist].
    Hamajima N
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):319-22. PubMed ID: 7880101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.